Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant - Takeaways - MDSpire

Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant

A meta-analysis led by a researcher at Roswell Park Comprehensive Cancer Center has identified key factors that could improve outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs) before or after a solid-organ transplant.

  • By

  • May 30, 2025

  • 4 min

Share

  • 1

    A meta-analysis led by Dr. Muhammad Awidi examined immune checkpoint inhibitors (ICIs) in solid-organ transplant patients.

  • 2

    The study analyzed 198 studies involving 331 transplant patients, revealing varying rejection rates by organ type.

  • 3

    Rejection rates were highest in kidney transplant recipients at 46.3%, followed by heart and liver transplant recipients.

  • 4

    Patients receiving anti-PD1 therapy had a rejection rate of 40.6%, while anti-CTLA4 and anti-PDL1 had lower rates.

  • 5

    The research concludes that ICI therapy in transplant patients is high-risk yet promising, warranting further investigation.

Original Source(s)

Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant

  • by

  • May 30, 2025

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors